Amoy Diagnostics Co Ltd
SZSE:300685
Operating Margin
Amoy Diagnostics Co Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CN |
|
Amoy Diagnostics Co Ltd
SZSE:300685
|
8.5B CNY |
25%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
329.6B USD |
30%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
157.1B USD |
25%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
134.8B USD |
38%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114.6B USD |
38%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
115.9B AUD |
26%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
56B USD |
29%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
40.1B USD |
-5%
|
Amoy Diagnostics Co Ltd
Glance View
Amoy Diagnostics Co., Ltd., nestled in the bustling city of Xiamen, China, has carved out a niche in the world of molecular diagnostics. Founded in 2008, the company has quickly become a pioneer in precision medicine, focusing on the development and commercialization of technologies for the detection of genetic mutations. At the heart of its operation lies its proprietary ADx-ARMS technology, an innovative method allowing for the precise and sensitive detection of mutations in tumor tissues and blood, facilitating oncology diagnostics. This technology not only empowers oncologists with critical insights for tailored cancer treatments but underscores Amoy Diagnostics' commitment to transforming patient care through cutting-edge genetic testing. The commercial prowess of Amoy Diagnostics is, however, much more than its technological innovations. The company thrives on a robust business model that hinges on a symbiotic relationship with the pharmaceutical industry and healthcare providers. By offering diagnostic services and research kits, Amoy Diagnostics provides crucial support in the development of targeted therapies, enabling pharmaceutical companies to test and bring to market personalized medicine solutions. Their revenue stream is bolstered by strategic partnerships and licensing agreements, which allow them to expand their portfolio and market reach both domestically and internationally. This dynamic approach not only ensures a wide adoption of their diagnostic solutions but also firmly positions Amoy Diagnostics as a key player in the rapidly growing field of precision oncology.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Amoy Diagnostics Co Ltd's most recent financial statements, the company has Operating Margin of 25.2%.
You don't have any saved screeners yet